Innovative gel offers hope against resistant infections in trial
Recce Pharmaceuticals has announced promising outcomes from the Phase II trial of their innovative RECCE 327 Topical Gel (R327G), signaling a potential breakthrough in the fight against antibiotic-resistant infections. This new gel is being developed to treat Acute Bacterial Skin and Skin Structure Infections (ABSSSI), offering hope where traditional treatments falter. The trial recently completed…